

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Jotham W. Coe :
APPLICATION NO.: 10/824,037 : Examiner: Rahmani, Niloofar
FILING DATE: April 14, 2004 : Group Art Unit: 1625
TITLE: 3-AZABICYCLO[3.2.1]OCTANE DERIVATIVES :

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


A first Office Action on the merits has been received; therefore, a fee for this Information Disclosure Statement is required. Please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached from PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Date: November 7, 2006


Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871

